Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.

Bovine papillomaviruses types 1 and 2 (BPV1, BPV2) commonly induce skin tumours termed sarcoids in horses and other equids. Sarcoids seriously compromise the health and welfare of affected individuals due to their propensity to resist treatment and reoccur in a more severe form. We have developed in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christoph Jindra, Edmund K Hainisch, Andrea Rümmele, Markus Wolschek, Thomas Muster, Sabine Brandt
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/86d2dd8891534c0c8903c2cdcd0e884f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:86d2dd8891534c0c8903c2cdcd0e884f
record_format	dspace
spelling	oai:doaj.org-article:86d2dd8891534c0c8903c2cdcd0e884f2021-12-02T20:12:39ZInfluenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.1932-620310.1371/journal.pone.0260155https://doaj.org/article/86d2dd8891534c0c8903c2cdcd0e884f2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0260155https://doaj.org/toc/1932-6203Bovine papillomaviruses types 1 and 2 (BPV1, BPV2) commonly induce skin tumours termed sarcoids in horses and other equids. Sarcoids seriously compromise the health and welfare of affected individuals due to their propensity to resist treatment and reoccur in a more severe form. We have developed influenza (Flu) A and B virus vectors that harbour a truncated NS1 gene (iNS) assuring interferon induction and co-express shuffled BPV1 E6 and E7 antigens for sarcoid immunotherapy. In a safety trial involving 12 healthy horses, intradermal administration of iNSA/E6E7equ and iNSB/E6E7equ was well tolerated, with the only transient side effect being mild fever in four horses. Repeated screening of secretions and faeces by RT-PCR and plaque assay revealed no virus shedding, thus also confirming biological safety. In a patient trial involving 29 horses bearing BPV1-induced single or multiple sarcoids, at least one lesion per horse was intratumourally injected and then boosted with iNSA/E6E7equ and/or iNSB/E6E7equ. The treatment induced a systemic antitumour response as reflected by the synchronous regression of injected and non-injected lesions. Irrespective of vaccination schemes, complete tumour regression was achieved in 10/29 horses. In 10/29 horses, regression is still ongoing (May 2021). Intriguingly, scrapings collected from former tumour sites in two patients tested negative by BPV1 PCR. Nine severely affected individuals with a history of unsuccessful therapeutic attempts did not (6/29) or only transiently (3/29) respond to the treatment. INSA/E6E7equ and iNSB/E6E7equ proved safe and effective in significantly reducing the tumour burden even in severe cases.Christoph JindraEdmund K HainischAndrea RümmeleMarkus WolschekThomas MusterSabine BrandtPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0260155 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Christoph Jindra Edmund K Hainisch Andrea Rümmele Markus Wolschek Thomas Muster Sabine Brandt Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.
description	Bovine papillomaviruses types 1 and 2 (BPV1, BPV2) commonly induce skin tumours termed sarcoids in horses and other equids. Sarcoids seriously compromise the health and welfare of affected individuals due to their propensity to resist treatment and reoccur in a more severe form. We have developed influenza (Flu) A and B virus vectors that harbour a truncated NS1 gene (iNS) assuring interferon induction and co-express shuffled BPV1 E6 and E7 antigens for sarcoid immunotherapy. In a safety trial involving 12 healthy horses, intradermal administration of iNSA/E6E7equ and iNSB/E6E7equ was well tolerated, with the only transient side effect being mild fever in four horses. Repeated screening of secretions and faeces by RT-PCR and plaque assay revealed no virus shedding, thus also confirming biological safety. In a patient trial involving 29 horses bearing BPV1-induced single or multiple sarcoids, at least one lesion per horse was intratumourally injected and then boosted with iNSA/E6E7equ and/or iNSB/E6E7equ. The treatment induced a systemic antitumour response as reflected by the synchronous regression of injected and non-injected lesions. Irrespective of vaccination schemes, complete tumour regression was achieved in 10/29 horses. In 10/29 horses, regression is still ongoing (May 2021). Intriguingly, scrapings collected from former tumour sites in two patients tested negative by BPV1 PCR. Nine severely affected individuals with a history of unsuccessful therapeutic attempts did not (6/29) or only transiently (3/29) respond to the treatment. INSA/E6E7equ and iNSB/E6E7equ proved safe and effective in significantly reducing the tumour burden even in severe cases.
format	article
author	Christoph Jindra Edmund K Hainisch Andrea Rümmele Markus Wolschek Thomas Muster Sabine Brandt
author_facet	Christoph Jindra Edmund K Hainisch Andrea Rümmele Markus Wolschek Thomas Muster Sabine Brandt
author_sort	Christoph Jindra
title	Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.
title_short	Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.
title_full	Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.
title_fullStr	Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.
title_full_unstemmed	Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.
title_sort	influenza virus vector ins1 expressing bovine papillomavirus 1 (bpv1) antigens efficiently induces tumour regression in equine sarcoid patients.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/86d2dd8891534c0c8903c2cdcd0e884f
work_keys_str_mv	AT christophjindra influenzavirusvectorins1expressingbovinepapillomavirus1bpv1antigensefficientlyinducestumourregressioninequinesarcoidpatients AT edmundkhainisch influenzavirusvectorins1expressingbovinepapillomavirus1bpv1antigensefficientlyinducestumourregressioninequinesarcoidpatients AT andrearummele influenzavirusvectorins1expressingbovinepapillomavirus1bpv1antigensefficientlyinducestumourregressioninequinesarcoidpatients AT markuswolschek influenzavirusvectorins1expressingbovinepapillomavirus1bpv1antigensefficientlyinducestumourregressioninequinesarcoidpatients AT thomasmuster influenzavirusvectorins1expressingbovinepapillomavirus1bpv1antigensefficientlyinducestumourregressioninequinesarcoidpatients AT sabinebrandt influenzavirusvectorins1expressingbovinepapillomavirus1bpv1antigensefficientlyinducestumourregressioninequinesarcoidpatients
_version_	1718374896088645632

Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.

Ejemplares similares